<DOC>
	<DOC>NCT01768195</DOC>
	<brief_summary>The purpose of this study is to identify the effect of prophylactic entecavir in HBsAg Positive lymphoma patients treated with rituximab-based immunochemotherapy.</brief_summary>
	<brief_title>Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based Immunochemotherapy</brief_title>
	<detailed_description>HBsAg Positive lymphoma patients are treated with entecavir when they receive rituximab-based immunochemotherapy. Entecavir 0.5mg daily is administrated from day 1 of immunochemotherapy and/or chemotherapy to 12 months after completing immunochemotherapy and/or chemotherapy.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>treatmentnaive patients with Bcell lymphoma HBsAg positive at baseline treated with rituximabbased immunochemotherapy life expectancy of more than 3 months younger than 18 years old HBsAg negative at baseline pregnant or lactating women</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Lymphoma</keyword>
	<keyword>Hepatitis B Virus</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>rituximab</keyword>
</DOC>